Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Share :
Published: 29 Sep 2012
Views: 9009
Dr Tony Mok - Chinese University of Hong Kong

Dr Tony Mok, professor in the Department of Clinical Oncology at the Chinese University of Hong Kong, reported data at a press conference at ESMO 2012 in Vienna, from an exploratory study which suggests that EGFR mutations may help to achieve this goal in patients with lung cancer.


The analysis was conducted using tumour and/or plasma mutation data from 347 patients who took part in the MISSION trial. EGFR and KRAs mutations were detected in 26% and 20% patients, respectively, and were well balanced between treatment arms, the researchers report.


ecancerNews Coverage from ESMO 2012